Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults

Machmutow, Katja; Meister, Richard; Jansen, A.; Kriston, Levente; Watzke, Birgit; Härter, Martin; Liebherz, Sarah

doi:10.1002/14651858.cd012855.pub2

Cited by 33 publications

(18 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the available pharmacological treatment options, efficacy is limited, especially for preventing relapse and recurrence [ 92 ]. For example, one in three patients diagnosed with MDD develops resistance to antidepressant drugs.…”

Section: Role Of Cbd On Anxiety and Depressive Disorders: Animal Amentioning

confidence: 99%

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

et al. 2020

View full text Add to dashboard Cite

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.

show abstract

Section: Role Of Cbd On Anxiety and Depressive Disorders: Animal Amentioning

confidence: 99%

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It can be understood as a complex neurobiological condition and the underlying pathophysiology is still poorly understood [ 2 ]. The overall effectiveness of available depression treatments is limited, a fact mirrored by high rates of relapse of the disease [ 3 ]. Both high prevalence rates and unsatisfying treatment outcomes have led to intense research efforts during the last decades to understand the neurobiological pathways underlying depression and optimize its treatment [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Differential Alterations in Resting State Functional Connectivity Associated with Depressive Symptoms and Early Life Adversity

et al. 2021

View full text Add to dashboard Cite

Depression and early life adversity (ELA) are associated with aberrant resting state functional connectivity (FC) of the default mode (DMN), salience (SN), and central executive networks (CEN). However, the specific and differential associations of depression and ELA with FC of these networks remain unclear. Applying a dimensional approach, here we analyzed associations of FC between major nodes of the DMN, SN, and CEN with severity of depressive symptoms and ELA defined as childhood abuse and neglect in a sample of 83 healthy and depressed subjects. Depressive symptoms were linked to increased FC within the SN and decreased FC of the SN with the DMN and CEN. Childhood abuse was associated with increased FC within the SN, whereas childhood neglect was associated with decreased FC within the SN and increased FC between the SN and the DMN. Our study thus provides evidence for differential associations of depressive symptoms and ELA with resting state FC and contributes to a clarification of previously contradictory findings. Specific FC abnormalities may underlie specific cognitive and emotional impairments. Future research should link specific clinical symptoms resulting from ELA to FC patterns thereby characterizing depression subtypes with specific neurobiological signatures.

show abstract

“…The risk of bias assessment was evaluated using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions [ 24 ] (including the domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias). In line with a previous operationalization [ 27 ], we specified the domain other bias using the following 3 categories: insufficient treatment adherence, allegiance bias, and attention bias.…”

Section: Methodsmentioning

confidence: 99%

“…Adverse events: any types of adverse events occurring during or after treatment, including physical symptoms (eg, headache); psychological symptoms (eg, depressed mood); and psychosocial, legal, and economic consequences (eg, conflicts with the partner) [ 27 ].…”

Section: Methodsmentioning

confidence: 99%

Evidence on Technology-Based Psychological Interventions in Diagnosed Depression: Systematic Review

Köhnen¹,

Dreier²,

Seeralan³

et al. 2021

JMIR Ment Health

Self Cite

View full text Add to dashboard Cite

Background Evidence on technology-based psychological interventions (TBIs) for the treatment of depression is rapidly growing and covers a broad scope of research. Despite extensive research in this field, guideline recommendations are still limited to the general effectiveness of TBIs. Objective This study aims to structure evidence on TBIs by considering different application areas (eg, TBIs for acute treatment and their implementation in health care, such as stand-alone interventions) and treatment characteristics (eg, therapeutic rationale of TBIs) to provide a comprehensive evidence base and to identify research gaps in TBIs for diagnosed depression. Moreover, the reporting of negative events in the included studies is investigated in this review to enable subsequent safety assessment of the TBIs. Methods Randomized controlled trials on adults diagnosed with unipolar depression receiving any kind of psychotherapeutic treatment, which was at least partly delivered by a technical medium, were eligible for inclusion in our preregistered systematic review. We searched for trials in CENTRAL (Cochrane Central Register of Controlled Trials; until August 2020), MEDLINE, PsycINFO, PSYNDEX, CINAHL; until the end of January 2018), clinical trial registers, and sources of gray literature (until the end of January 2019). Study selection and data extraction were conducted by 2 review authors independently. Results Database searches resulted in 15,546 records, of which 241 publications were included, representing 83 completed studies and 60 studies awaiting classification (ie, preregistered studies, study protocols). Almost all completed studies (78/83, 94%) addressed the acute treatment phase, being largely either implemented as stand-alone interventions (66/83, 80%) or blended treatment approaches (12/83, 14%). Studies on TBIs for aftercare (4/83, 5%) and for bridging waiting periods (1/83, 1%) were scarce. Most TBI study arms (n=107) were guided (59/107, 55.1%), delivered via the internet (80/107, 74.8%), and based on cognitive behavioral treatment approaches (88/107, 79.4%). Almost all studies (77/83, 93%) reported information on negative events, considering dropouts from treatment as a negative event. However, reports on negative events were heterogeneous and largely unsystematic. Conclusions Research has given little attention to studies evaluating TBIs for aftercare and for bridging waiting periods in people with depression, even though TBIs are seen as highly promising in these application areas; thus, high quality studies are urgently needed. In addition, the variety of therapeutic rationales on TBIs has barely been represented by identified studies hindering the consideration of patient preferences when planning treatment. Finally, future studies should use specific guidelines to systematically assess and report negative events. Trial Registration International Prospective Register of Systematic Reviews (PROSPERO) CRD42016050413; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42016050413. International Registered Report Identifier (IRRID) RR2-10.1136/bmjopen-2018-028042

show abstract

Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults

Cited by 33 publications

References 91 publications

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Differential Alterations in Resting State Functional Connectivity Associated with Depressive Symptoms and Early Life Adversity

Evidence on Technology-Based Psychological Interventions in Diagnosed Depression: Systematic Review

Contact Info

Product

Resources

About